<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="Tab1">
 <label>Table 1</label>
 <caption>
  <p>Definition of additional risk minimisation measures as laid down in GVP module XVI rev 2 [
   <xref ref-type="bibr" rid="CR4">4</xref>]
  </p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th align="left">Additional risk minimisation measures</th>
    <th align="left"/>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td align="left">Educational programmes</td>
    <td align="left">
     <p>Educational programmes are based on targeted communication with the aim to supplement the information in the Summary of Product Characteristics and Patient Information Leaflet. Any educational material should focus on actionable goals and should provide clear and concise messages describing actions to be taken in order to prevent and minimise selected risks</p>
     <p>Educational materials can be aimed toward healthcare professionals and/or patients/caregivers</p>
    </td>
   </tr>
   <tr>
    <td align="left">Controlled access programme</td>
    <td align="left">A controlled access programme consists of interventions seeking to control access to a medicinal product beyond the level of control ensured by routine risk minimisation measures, i.e. the legal status</td>
   </tr>
   <tr>
    <td align="left">Controlled distribution system</td>
    <td align="left">A controlled distribution system refers to the set of measures implemented to ensure that the stages of the distribution chain of a medicinal product are tracked up to the prescription and/or pharmacy dispensing the product</td>
   </tr>
   <tr>
    <td align="left">Pregnancy prevention programme</td>
    <td align="left">A pregnancy prevention programme is a set of interventions aimed at minimising pregnancy exposure during treatment with a medicinal product with known or potential teratogenic effects</td>
   </tr>
  </tbody>
 </table>
</table-wrap>
